For the six months ended June 30, 2025, general and administrative expenses were $1.9 million, compared to $1.5 million for the six months ended June 30, 2024. The increase was mainly attributable to higher legal costs and share-based compensation expenses. Research and development expenses were $0.3 million for the six months ended June 30, 2025, compared to $11.4 million for the six months ended June 30, 2024. The decrease was primarily due to the completion of the Phase 3 clinical trial evaluating PRF-110 in 2024. Financial income, net, was $52,000 for the six months ended June 30, 2025, compared to $92,000 for the six months ended June 30, 2024. The decrease was primarily due to lower cash balances in 2025. Net loss for the six months ended June 30, 2025, was $2.3 million, compared to $12.8 million for the six months ended June 30, 2024. As of June 30, 2025, cash and cash equivalents (including restricted cash) were $3.5 million, and working capital was $1.5 million.